Eyeing accelerated approval for Duchenne gene therapy, Sarepta hopes to bring in $1B in bid for profitability

On Monday, Alnylam announced that it was looking to raise $900 million on the back of a positive readout for its drug in ATTR …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eye­ing ac­cel­er­at­ed ap­proval for Duchenne gene ther­a­py, Sarep­ta hopes to bring in $1B in bid for prof­itabil­i­ty